Mammalian target of rapamycin inhibitor-associated stomatitis

NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy

(2017) Gary R. Hudes et al.   Journal of the National Comprehensive Cancer Network

A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients

(2013) Fabiana Martins et al.   ORAL ONCOLOGY

Experiences with the FACT-EGFRI-18 instrument in EGFRI-associated mucocutaneous adverse events

(2013) Christine B. Boers-Doets et al.   SUPPORTIVE CARE IN CANCER

New developments in management of oral mucositis in patients with head and neck cancer or receiving targeted anticancer therapies

(2012) E. Li et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Viral loads and antiviral resistance of herpesviruses and oral ulcerations in hematopoietic stem cell transplant recipients

(2012) M T van der Beek et al.   BONE MARROW TRANSPLANTATION

Oral bacteria and yeasts in relationship to oral ulcerations in hematopoietic stem cell transplant recipients

(2012) Alexa M. G. A. Laheij et al.   SUPPORTIVE CARE IN CANCER

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma

(2011) Camillo Porta et al.   EUROPEAN JOURNAL OF CANCER

Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies

(2011) Janet E Dancey et al.   Future Oncology

Vanderbilt head and neck symptom survey version 2.0: Report of the development and initial testing of a subscale for assessment of oral health

(2011) Emily Cooperstein et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

(2011) Seth A. Wander et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas

(2011) Sant P. Chawla et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral Adverse Events Associated with Tyrosine Kinase and Mammalian Target of Rapamycin Inhibitors in Renal Cell Carcinoma: A Structured Literature Review

(2011) C. B. Boers-Doets et al.   ONCOLOGIST

Clinical presentation and management of mTOR inhibitor-associated stomatitis

(2011) Marcio Augusto de Oliveira et al.   ORAL ONCOLOGY

Oral complications of targeted cancer therapies: A narrative literature review

(2011) A.L. Watters et al.   ORAL ONCOLOGY

Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives

(2011) Marc Dufour et al.   Cancers

mTOR inhibitor-associated dermatologic and mucosal problems

(2010) Josep M. Campistol et al.   CLINICAL TRANSPLANTATION

Aphthous ulcers

(2010) Diana V. Messadi et al.   Dermatologic Therapy

Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach

(2010) Ronald M Bukowski   EXPERT OPINION ON PHARMACOTHERAPY

Dysfunction of CD4+CD25high T regulatory cells in patients with recurrent aphthous stomatitis

(2010) Natalia Lewkowicz et al.   JOURNAL OF ORAL PATHOLOGY & MEDICINE

FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma

(2010) V. E. Kwitkowski et al.   ONCOLOGIST

A systematic review of viral infections associated with oral involvement in cancer patients: a spotlight on Herpesviridea

(2010) Sharon Elad et al.   SUPPORTIVE CARE IN CANCER

A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact

(2010) S. B. Jensen et al.   SUPPORTIVE CARE IN CANCER

The Multifunctional Role of mTOR in Innate Immunity: Implications for Transplant Immunity

(2009) M. D. Säemann et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel

(2009) C. Sessa et al.   ANNALS OF ONCOLOGY

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib

(2009) W.J. Lee et al.   BRITISH JOURNAL OF DERMATOLOGY

Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity

(2009) Nielka P. van Erp et al.   JOURNAL OF CLINICAL ONCOLOGY

The multiple facets of mTOR in immunity

(2009) Thomas Weichhart et al.   TRENDS IN IMMUNOLOGY

Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features

(2008) J. Bellmunt et al.   ANNALS OF ONCOLOGY

Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies

(2008) T. E. Hutson et al.   ONCOLOGIST

Toxicities Associated with the Administration of Sorafenib, Sunitinib, and Temsirolimus and Their Management in Patients with Metastatic Renal Cell Carcinoma

(2007) Naeem Bhojani et al.   EUROPEAN UROLOGY